by Randy Miller | Sep 24, 2026 | FDA, FOIA, Hedge Funds
FOIAengine: Sofinnova Bet on Drug FDA Approved Last Week Shares of Ultragenyx Pharmaceutical Inc. rose 16 percent September 17 after the Food and Drug Administration approved Fayuvi, its gene therapy for Sanfilippo syndrome Type A, a rare and devastating genetic...
by John A. Jenkins | Sep 9, 2026 | FOIA, Non-Profits, Politics
FOIAengine: Hundreds of Requests Targeted Biden Connections at Center for American Progress Months before Donald Trump threatened the Center for American Progress, the influential progressive policy organization, with a $5 billion defamation lawsuit,...
by John A. Jenkins | Sep 3, 2026 | FDA, FOIA
FOIAengine: Newly Remade Advisory Committee Green Lights Six Compounds, Despite the Applications Being Pulled Bobby Harshbarger is a Tennessee state senator and pharmacist of noteworthy lineage, with an interesting backstory. Both of his parents are...
by Randy Miller | Aug 20, 2026 | FDA, FOIA, News Media, Politics
FOIAengine: Twenty-One Requests from News Media, Non-Profits and Companies The nationwide outbreak of cyclospora infections this summer prompted a steady stream of national and local news articles, along with 21 Freedom of Information Act requests to the Food and Drug...
by John A. Jenkins | Aug 12, 2026 | FOIA, SEC
As the artificial-intelligence arms race heats up, Meta and Google have turned to Wall Street for help paying the multi-billion-dollar tab. Amid data-center financing terms that even Google’s auditor calls questionable, a Washington securities lawyer whose clients...
by John A. Jenkins | Aug 5, 2026 | FDA, FOIA, Hedge Funds, Pharmaceuticals, Stock Market
FOIAengine: Requests from Point72, Sofinnova, Holocene, Triple Gate and Others A review of the latest Freedom of Information Act requests targeting three life-sciences companies – Novo Nordisk (NYSE: NVO); Charles River Laboratories (NYSE: CRL); and iRhythm...
